Hematological Malignancies

The Hematologic Malignancy team at the Knight Diagnostic Laboratories performs diagnostic and clinically actionable tests developed at Oregon Health and Science University. The department includes a variety of molecular platforms which allow testing to be developed using the most appropriate technology for the application. Testing includes quantitative real-time PCR, high resolution melting curve (HRM) analyses, pyrosequencing, and Sanger sequencing. 

Our mass spectroscopy-based solid tumor panel (Sequenom^R platform) covers 370 mutations across 31 genes known to be important in cancer, one of the largest leukemia gene mutation panels available in the U.S.A. Positive results from these assays are confirmed by traditional Sanger sequencing. The Knight Diagnostic Laboratories is developing an AML/MDS panel in the GeneTrails™. More custom panels are in development and will be clinically available in the near future.

Tests are available for the following diseases:

Acute Myelogenous Leukemia

• NPM1
• FLT3 qualitative and quantitative
• cKIT
• WT1
• ERG
• DNMT3A
• CEBPA
• BAALC
• IDH1 & IDH2
• Multiplex leukemia panel using mass spectrometry

Chronic Myelogenous Leukemia

• BCR/ABL quantitative
• BCR/ABL Nested PCR (high sensitivity qualitative reflex test)
• BCR/ABL kinase domain mutation, qualitative and quantitative

Clonality

• B Cell Gene Rearrangement (IgH, reflexed to kappa, lambda)
• T Cell Gene Rearrangement (gamma/delta reflexed to beta)

Myeloproliferative Disorders

• JAK2 V617F qualitative and quantitative
• JAK2 exon 12

Mast Cell Disease

• CKIT (allele-specific, high sensitivity)

Links:

• Oncology
• Cancer Cytogenetics and FISH
• Solid Tumors
• Inherited Cancer Syndromes